Both the LEADER (liraglutide) and SUSTAIN-6 (subcutaneous semaglutide) trials reported significant reductions in the primary outcome (incidence of MACE).10,33 With regard to the secondary outcome of HF hospitalisation, the results were neutral, with LEADER showing a non-significant relative risk reduction (RRR) of 13% with liraglutide compared with placebo and SUSTAIN-6 showing no significant difference between the semaglutide and placebo treatment groups.10,33 Similarly, the REWIND trial, in patients with T2D and established CVD or cardiovascular risk factors, reported that dulaglutide significantly reduced the incidence of MACE (primary outcome)
Psychiatry 170 , 681682 (2013)
While Ozempic and other GLP-1 receptor agonists can help patients lose weight, they work best in conjunction with healthy lifestyle changes
Similar to other diabetes medicines, taking metformin can cause hypoglycemia (low blood sugar levels)
Its relevance during GLP-1 therapy is limited to general oxidative-stress support during caloric deficit not to amplifying or replacing medication effects
TrimRx explains how using glp 1 for weight loss in New Jersey often leads to more consistent energy throughout the day, especially when combined with a glp 1 probiotic
